Rockville, Maryland, and Taipei, Taiwan–16th July 2025— AAVnerGene Inc. and TFBS Bioscience Inc. today announced a collaboration on the development and application of innovative adeno-associated virus (AAV) vector technologies for manufacturing, including key areas such as AAV tropism enhancement and manufacturing process optimization.

AAVnerGene focuses on developing novel AAV technologies, including the improvement of AAV tropism and production efficiency. Its AAVone single-plasmid system can manufacture AAV with higher efficiency and purity, use less plasmid, and simplify production procedures. TFBS Bioscience specializes in one-stop-shop viral vector manufacturing services, from R&D and process development to GMP manufacturing and quality testing.

Under this collaboration, AAVnerGene and TFBS Bioscience will combine their expertise in early-stage platform research and GMP manufacturing to optimize AAV vector production technologies. TFBS Bioscience will conduct process development and GMP manufacturing, testing, and validation. Through the technology collaboration, both parties aim to refine production procedure and enhance commercial scalability. This partnership is expected to significantly reduce AAV manufacturing cost, promote the accessibility of gene therapy and provide clients highly efficient and competitive manufacturing solutions.  By combining their complementary strengths, both parties expect to expand manufacturing capabilities in the Asia-Pacific and North American markets, addressing diverse needs in manufacturing from research, preclinical, clinical to commercial stages.

 “Through this collaboration, AAVnerGene will leverage TFBS Bioscience’s GMP manufacturing capabilities to strengthen its presence in the East Asian market.” said Daozhan Yu, President and CEO at AAVnerGene, “As a trusted and certified CDMO, TFBS provides a strong foundation for translating our AAVone single-plasmid production system into commercial applications. We are pleased to work together to offer high-quality and cost-effective solutions to our partners, helping make gene therapy more accessible and affordable for patients worldwide.”

"We believe our collaboration with AAVnerGene will drive the development of innovative AAV vector technologies, to deliver safer and more effective gene therapies to patients worldwide”” said Dr. Tatung Yuan, Chairman and Chief Executive Officer at TFBS Bioscience, “TFBS Bioscience is dedicated to integrating this innovative technology platform into GMP-grade manufacturing to better serve the global gene therapy community."

This collaboration indicates the efforts of both parties in advancing innovative AAV vector applications for gene therapy, while emphasizing the manufacturing presence across the Asia-Pacific and North American markets to make gene therapy an affordable treatment option for patients.

About AAVnerGene
AAVnerGene Inc., headquartered in Rockville, Maryland, USA, is a biotechnology company dedicated to advancing gene therapy through AAV platform technologies. Founded in 2019, the team brings decades of experience in AAV gene therapy, supporting programs from early research through preclinical development. It offers integrated solutions including vector design, packaging, capsid library construction, and screening. The company’s vision is to overcome key challenges in AAV gene therapy, such as high dosing requirements, side effects, and cost, through novel technologies, ultimately making gene therapy more accessible to patients. AAVnerGene’s proprietary single-plasmid system, AAVone, achieves AAV yields up to 5E12 vg/mL. Additionally, using its ATHENA capsid screening platform, the company has identified AAV serotypes with high targeting efficiency to NHP brain, lung, and retinal tissues, significantly reducing the required dose of gene therapeutics.

About TFBS Bioscience Inc.

TFBS Bioscience Inc. (TFBS) was founded in 2016 as the first contract research organization providing biological testing in Taiwan after its spin-off from Development Center for Biotechnology, a government-sponsored research institute. TFBS has established strong track records in several regulatory submissions, winning trust from the international regulatory agencies and biopharmaceutical industry. TFBS has launched the first viral vector contract development and manufacturing facility in Taiwan, providing fully integrated end-to-end contract development and manufacturing services for the needs of clinical trials. TFBS offers manufacturing expertise in adeno-associated virus, lentivirus, and retrovirus.  With the customization specialty and state-of-the-art facility, TFBS is the best partner offering clients a one-stop-shop solution for gene and cell therapy. For more information, please visit www.tfbsbio.com.